Ajmal N, Bogart M, Khan P, Max-Harry I, Healy A, Nunemaker C
J Diabetes Res. 2024; 2024:5151171.
PMID: 39735417
PMC: 11679277.
DOI: 10.1155/jdr/5151171.
La Noce M, Nicoletti G, Papaccio G, Del Vecchio V, Papaccio F
Cells. 2022; 11(23).
PMID: 36497199
PMC: 9740394.
DOI: 10.3390/cells11233941.
den Hollander N, Roep B
Front Med (Lausanne). 2022; 9:932086.
PMID: 35903316
PMC: 9314738.
DOI: 10.3389/fmed.2022.932086.
Pearson J, McKinney E, Walker L
Immunother Adv. 2022; 1(1):ltab024.
PMID: 35156097
PMC: 8826223.
DOI: 10.1093/immadv/ltab024.
Wilhelm-Benartzi C, Miller S, Bruggraber S, Picton D, Wilson M, Gatley K
BMJ Open. 2021; 11(12):e053669.
PMID: 34876434
PMC: 8655536.
DOI: 10.1136/bmjopen-2021-053669.
Cyclosporine Treatment in Cats with Presumed Chronic Pancreatitis-A Retrospective Study.
Hoeyrup N, Spillmann T, Toresson L
Animals (Basel). 2021; 11(10).
PMID: 34680012
PMC: 8532754.
DOI: 10.3390/ani11102993.
100 years of insulin: celebrating the past, present and future of diabetes therapy.
Sims E, Carr A, Oram R, DiMeglio L, Evans-Molina C
Nat Med. 2021; 27(7):1154-1164.
PMID: 34267380
PMC: 8802620.
DOI: 10.1038/s41591-021-01418-2.
Therapeutic Potential of Alpha-1 Antitrypsin in Type 1 and Type 2 Diabetes Mellitus.
Park S, Ortega R, Agudelo C, Perez Perez J, Perez Gandara B, Garcia-Arcos I
Medicina (Kaunas). 2021; 57(4).
PMID: 33923873
PMC: 8073794.
DOI: 10.3390/medicina57040397.
A future for CD3 antibodies in immunotherapy of type 1 diabetes.
Chatenoud L
Diabetologia. 2019; 62(4):578-581.
PMID: 30612137
DOI: 10.1007/s00125-018-4808-7.
Target engagement and cellular fate of otelixizumab: a repeat dose escalation study of an anti-CD3ε mAb in new-onset type 1 diabetes mellitus patients.
Vlasakakis G, Napolitano A, Barnard R, Brown K, Bullman J, Inman D
Br J Clin Pharmacol. 2018; 85(4):704-714.
PMID: 30566758
PMC: 6422670.
DOI: 10.1111/bcp.13842.
Therapies to Suppress β Cell Autoimmunity in Type 1 Diabetes.
Kroger C, Clark M, Ke Q, Tisch R
Front Immunol. 2018; 9:1891.
PMID: 30166987
PMC: 6105696.
DOI: 10.3389/fimmu.2018.01891.
Stem Cell Therapies for Treating Diabetes: Progress and Remaining Challenges.
Sneddon J, Tang Q, Stock P, Bluestone J, Roy S, Desai T
Cell Stem Cell. 2018; 22(6):810-823.
PMID: 29859172
PMC: 6007036.
DOI: 10.1016/j.stem.2018.05.016.
Alpha-1 antitrypsin treatment of new-onset type 1 diabetes: An open-label, phase I clinical trial (RETAIN) to assess safety and pharmacokinetics.
Weir G, Ehlers M, Harris K, Kanaparthi S, Long A, Phippard D
Pediatr Diabetes. 2018; 19(5):945-954.
PMID: 29473705
PMC: 6030471.
DOI: 10.1111/pedi.12660.
The shifting paradigm of a "cure" for type 1 diabetes: is technology replacing immune-based therapies?.
Pettus J, von Herrath M
Acta Diabetol. 2017; 55(2):117-120.
PMID: 29188386
PMC: 5816711.
DOI: 10.1007/s00592-017-1069-8.
Have we pushed the needle for treatment of Type 1 diabetes?.
Naushad N, Perdigoto A, Rui J, Herold K
Curr Opin Immunol. 2017; 49:44-50.
PMID: 28992525
PMC: 5937133.
DOI: 10.1016/j.coi.2017.09.004.
Cell Therapy for Type 1 Diabetes: Current and Future Strategies.
Aghazadeh Y, Nostro M
Curr Diab Rep. 2017; 17(6):37.
PMID: 28432571
DOI: 10.1007/s11892-017-0863-6.
Anti-coreceptor therapy drives selective T cell egress by suppressing inflammation-dependent chemotactic cues.
Martin A, Clark M, Gojanovich G, Manzoor F, Miller K, Kline D
JCI Insight. 2016; 1(17):e87636.
PMID: 27777971
PMC: 5070954.
DOI: 10.1172/jci.insight.87636.
Immune-Modulating Therapy for Rheumatologic Disease: Implications for Patients with Diabetes.
Pilla S, Quan A, Germain-Lee E, Hellmann D, Mathioudakis N
Curr Diab Rep. 2016; 16(10):91.
PMID: 27525682
PMC: 6031126.
DOI: 10.1007/s11892-016-0792-9.
Progress and challenges for treating Type 1 diabetes.
Garyu J, Meffre E, Cotsapas C, Herold K
J Autoimmun. 2016; 71:1-9.
PMID: 27210268
PMC: 4903889.
DOI: 10.1016/j.jaut.2016.04.004.
Interleukin-1 antagonism moderates the inflammatory state associated with Type 1 diabetes during clinical trials conducted at disease onset.
Cabrera S, Wang X, Chen Y, Jia S, Kaldunski M, Greenbaum C
Eur J Immunol. 2015; 46(4):1030-46.
PMID: 26692253
PMC: 4828314.
DOI: 10.1002/eji.201546005.